• is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.


  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.


I have read and understood the above

Drug research and development » Explaining drug development

Explaining drug development

Click on the image hotspots or use the labelled buttons on the left to find out more.

The process of drug discovery begins with biomedical research into the pathophysiology of a particular disease with an aim to translate this research into the development of a clinical therapy. This process can take between 10–15 years and is outlined below.

Drug target identification

This is the identification of a potential therapeutic drug target, including understanding its role in the disease process. In CF, discovery of the CFTR gene enabled researchers to have a better understanding of the pathophysiologic processes underlying the disease, thereby accelerating the development of targeted therapies.

Preclinical research

After a candidate drug is identified, in vitro and animal studies are performed to evaluate the pharmacodynamics, pharmacokinetics and toxicology of the pharmaceutical agent. Recommended doses and an accompanying safety profile are generated from this information.

Phase I clinical trials

This is the first stage in testing a novel therapy in humans. These investigations are designed to gather preliminary information on the pharmacokinetics, dosage, safety and tolerability of the drug in about 20 healthy volunteers. Phase I trials are usually performed without a comparison group.

Phase II clinical trials

In phase II trials, the investigational therapy is administered to a relatively larger group of patients (20–400) suffering from the disease. The main objective is to ascertain drug efficacy, with continued evaluation to evaluate safety further. Treatment period per patient is about 1 to 3 months. Occasionally, phase II studies are subdivided into phase IIa, which specifically assess dosing of the therapeutic agent, and phase IIb.

Phase III clinical trials

In phase III trials, the study drug or treatment is given to larger groups of people (1000–3000) to assess its efficacy and any safety signals compared with placebo and commonly used treatments. Most phase III drug trials are designed as randomised, double-blind and placebo-controlled:

  • Randomised: Each participant is randomly assigned to receive either the trial treatment or a placebo
  • Blind: In a ‘blind study’ the participants are not informed if they are receiving the study drug or a placebo. In a double-blind trial, study investigators are also not informed about who is receiving the trial drug or placebo. ‘Blinding’ is intended to prevent potential biases from either the treating healthcare professional or the participant.

Regulatory review (and approval)

Results of clinical trials along with supporting preclinical and clinical data are collated and submitted to the relevant regulatory authorities to obtain approval to market the drug in their jurisdiction (e.g. a New Drug Application [NDA] in the USA, and a Marketing Authorisation Application [MAA] in the EU).

Phase IV

Once a drug has been approved, the manufacturer must submit marketing authorisation applications in every country or territory where the drug is to be marketed. Phase IV clinical trials are conducted to support these applications and to continue evaluating the drug’s safety and efficacy.